( MENAFN - GetNews) According to the experts at Creative Biolabs, LBP commercialization will become a clever strategy in systems biology which they are ready to embrace with full technological capabilities. New York, USA - November 11, 2024 - Pharmaceutical and research organizations across the world have taken a particular interest in live biotherapeutic products (LBPs) with various applications such as immunotherapy or antibacterial therapies due to their unique characteristics. Microbial Identification Within the life cycle of developing LBPs, the most important step includes microbial identification.
Traditional microbial identification techniques are restricted by culture methods, resulting in an inability to isolate and accurately identify all microorganisms present in complex samples. "Traditional methods of identification came up short," said an expert from Creative Biolabs. "We have adopted genome-based identification methods that include, among others, 16S rRNA sequencing , which is fast, accurate, and avoids constraints posed by traditional identification methods.
" Microbial identification is often a routine and simple activity performed at many clinical microbiology laboratories, but it is believed that 16S rRNA sequencing has reduced ambiguity and is much more accurate. Creative Biolabs employs this method to perform identifications through sequence analysis. In comparison to traditional cultivation procedures, PCR-based 16S rRNA sequencing is a rapid and sensiti.
